Use Caution/Monitor. OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Modify Therapy/Monitor Closely. Information last revised December 2021. Other (see comment). Modify Therapy/Monitor Closely. Avoid or Use Alternate Drug. 0000003468 00000 n Use Caution/Monitor. To view formulary information first create a list of plans. Use Caution/Monitor.

hb````` @Q3%Sgm8y-=}.DA 0@`U?i H3 a#crFGkr Iek1k20r3Pdfb>pAAuL-b 9[]4S@/ #3 Avoid or Use Alternate Drug. Applies only to oral form of both agents. nafcillin will decrease the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Use Caution/Monitor. Minor/Significance Unknown. zidovudine increases toxicity of doxorubicin liposomal by pharmacodynamic synergism. 0000124455 00000 n Use Caution/Monitor. Coadministration may increase risk for adverse effects of CYP3A4 substrates. Used in the treatment of cancer. Monitor Closely (1)rucaparib will increase the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Copyright 2022 MIMS Pte Ltd. All rights reserved. Otherwise, call a poison control center right away. 0000009919 00000 n

Use Caution/Monitor. atazanavir will increase the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor Closely (1)nefazodone will increase the level or effect of doxorubicin liposomal by P-glycoprotein (MDR1) efflux transporter. Inreased risk of myelosuppression. butabarbital will decrease the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. quinidine will increase the level or effect of doxorubicin liposomal by P-glycoprotein (MDR1) efflux transporter. fedratinib will increase the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Either increases toxicity of the other by unknown mechanism. dacomitinib will increase the level or effect of doxorubicin liposomal by affecting hepatic enzyme CYP2D6 metabolism. doxorubicin liposomal decreases effects of influenza virus vaccine quadrivalent, adjuvanted by pharmacodynamic antagonism. Monitor Closely (1)doxorubicin liposomal decreases levels of ethotoin by increasing metabolism. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Use Caution/Monitor.

givosiran will increase the level or effect of doxorubicin liposomal by affecting hepatic enzyme CYP2D6 metabolism. Serious - Use Alternative (1)lorlatinib will decrease the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

Use Caution/Monitor. Modify Therapy/Monitor Closely. If coadministration of lonafarnib (a sensitive CYP3A substrate) with weak CYP3A inhibitors is unavoidable, reduce to, or continue lonafarnib at starting dose. Avoid or Use Alternate Drug. 0000001176 00000 n Comment: Concomitant administration of zidovudine and doxorubicin should be avoided since an antagonistic relationship has been demonstrated in vitro. Use Caution/Monitor. doxorubicin liposomal decreases effects of sipuleucel-T by pharmacodynamic antagonism. Comment: Caution should be taken in patients on concomitant immunosuppressants or with impaired immune systems because of increased risk for serious infections. Avoid or Use Alternate Drug. Modify Therapy/Monitor Closely.

Avoid or substitute another drug for these medications when possible. Sunlight may worsen any skin reactions that may occur while you are using this drug. Modify Therapy/Monitor Closely. Inreased risk of myelosuppression.doxorubicin liposomal decreases effects of zidovudine by Other (see comment). Use Caution/Monitor.cyclosporine will increase the level or effect of doxorubicin liposomal by P-glycoprotein (MDR1) efflux transporter. erythromycin base will increase the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses <100 mg. dexamethasone will decrease the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. <> endobj provider for the most current information. Minor/Significance Unknown. Consult your doctor for more details. [201 0 R] Minor/Significance Unknown. Use Caution/Monitor. Monitor Closely (1)dichlorphenamide and doxorubicin liposomal both decrease serum potassium. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses <100 mg. Monitor Closely (1)dexamethasone will decrease the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased risk of hemorrhagic cystitis. . Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments. This effect was not observed with istradefylline 20 mg/day. Use Caution/Monitor. belatacept and doxorubicin liposomal both increase immunosuppressive effects; risk of infection. phenytoin will decrease the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.erythromycin ethylsuccinate will increase the level or effect of doxorubicin liposomal by P-glycoprotein (MDR1) efflux transporter. Monitor Closely (1)aprepitant will increase the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. Monitor Closely (1)primidone will decrease the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)nevirapine will decrease the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Use Caution/Monitor. mKh/(;~4Y!/xTprW-q Lipo-Dox exhibits unique pharmacokinetic properties and must not be used interchangeably with other formulations of doxorubicin hydrochloride. itraconazole will increase the level or effect of doxorubicin liposomal by P-glycoprotein (MDR1) efflux transporter. Avoid freezing. phenytoin will decrease the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Modify Therapy/Monitor Closely. Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. Avoid prolonged sun exposure, tanning booths and sunlamps. STORAGE: Consult the product instructions and your pharmacist for storage details. Use Caution/Monitor.

Modify Therapy/Monitor Closely. Use Caution/Monitor. unknown mechanism. doxorubicin liposomal, hydroxyurea. crizotinib increases levels of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. elagolix will increase the level or effect of doxorubicin liposomal by P-glycoprotein (MDR1) efflux transporter. %PDF-1.7 % Consider dose reduction of the sensitive CYP3A4 substrate(s) if unable to avoid. If possible, avoid coadministration or modify dose of BCRP substrate coadministered with fostemsavir. endobj Modify Therapy/Monitor Closely. USES: Liposomal doxorubicin is an anthracycline-type chemotherapy drug that is used to treat certain types of cancer (such as ovarian cancer, AIDS-related Kaposi's sarcoma, multiple myeloma). artemether/lumefantrine will decrease the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. endobj By clicking send, you acknowledge that you have permission to email the recipient with this information. Monitor Closely (1)rifabutin will decrease the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors. Use Caution/Monitor. 169 0 obj Use Caution/Monitor. 182 0 obj Fostemsavir inhibits BCRP transporters. Serious - Use Alternative (1)doxorubicin liposomal will increase the level or effect of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. unspecified interaction mechanism. Elagolix is a weak-to-moderate CYP3A4 inducer. x}Rj0+tl/ch\>tn?SA-Y9$Mbf"MR7/'f-XK%Lp{8HhvANy04QY'kf,=0Rw:UD~I+93f Lc3|0PIpsBU|Q{^;6!r~bn],__',\~l"ET/(x3&=Oni9CCihiiik Increase dose of CYP3A4 substrate, as needed, when coadministered with cenobamate. To decrease the risk, limit hot foods and drinks, brush your teeth carefully, avoid using mouthwash that contains alcohol, and rinse your mouth frequently with cool water.Get medical help right away if this rare but very serious side effect occurs: chest pain.Within days to weeks after doxorubicin treatment, a serious skin reaction that looks likes a severe sunburn (radiation recall) may develop on any area of skin that has been previously treated with radiation. carbamazepine will decrease the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Minor/Significance Unknown. The symptoms can be made worse by heat/pressure on your hands/feet. Monitor Closely (2)erythromycin lactobionate will increase the level or effect of doxorubicin liposomal by P-glycoprotein (MDR1) efflux transporter. SIDE EFFECTS: See also Warning section.Body aches/pains, headache, nausea, vomiting, constipation, diarrhea, stomach upset, and loss of appetite may occur. Use Caution/Monitor. Evaluate for loss of therapeutic effect if medication must be coadministered. Monitor Closely (1)fostemsavir will increase the level or effect of doxorubicin liposomal by Other (see comment). Serious - Use Alternative (1)ribociclib will increase the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)amiodarone will increase the level or effect of doxorubicin liposomal by P-glycoprotein (MDR1) efflux transporter. unknown mechanism. Use Caution/Monitor. dronedarone will increase the level or effect of doxorubicin liposomal by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Avoid or Use Alternate Drug. 0 n\ Monitor Closely (2)rifampin will decrease the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. 0000012893 00000 n Minor/Significance Unknown. CYP3A4 substrates may require dosage adjustment. Use Caution/Monitor. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine. 0000002066 00000 n Monitor Closely (2)lapatinib will increase the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Cobicistat is a CYP2D6 inhibitor; caution with CYP2D6 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events. Manage and view all your plans together even plans in different states. Use Caution/Monitor. fosphenytoin will decrease the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. endobj endobj startxref Comment: Palifermin should not be administered within 24 hrbefore, during infusion of, or within 24 hr after administration of antineoplastic agents. Monitor Closely (1)doxorubicin liposomal, denosumab. Other (see comment). Monitor Closely (1)streptozocin increases levels of doxorubicin liposomal by decreasing metabolism. Use Caution/Monitor. doxorubicin liposomal will increase the level or effect of lemborexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. cimetidine will increase the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Fexinidazole inhibits CYP3A4. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the P-gp substrate and titrate to clinical effect.eliglustat increases levels of doxorubicin liposomal by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. The recipient will receive more details and instructions to access this offer. Modify Therapy/Monitor Closely. Use Caution/Monitor. Increased risk of hepatotoxicity. lorcaserin will increase the level or effect of doxorubicin liposomal by affecting hepatic enzyme CYP2D6 metabolism. Pegylated liposomal doxorubicin is embryotoxic in rats and embryotoxic and abortifacient in rabbits. stiripentol, doxorubicin liposomal. endobj Avoid or Use Alternate Drug. 0000013346 00000 n Voxelotor increases systemic exposure of sensitive CYP3A4 substrates. P-gp inducers reduce systemic exposure of dabigatran. Your doctor will give you a pregnancy test before starting treatment. It works by slowing or stopping cancer cell growth. Avoid or Use Alternate Drug. Use Caution/Monitor. endobj hbbf`b``3 Avoid concomitant use of tucatinib with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If your partner becomes pregnant or thinks she may be pregnant, tell the doctor right away.This medication passes into breast milk. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents.

Consider increasing CYP3A substrate dose if needed. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. Use Caution/Monitor. Men with a female partner of childbearing age who is not pregnant should ask about reliable forms of birth control to use during treatment with this medication and for 3 months after stopping treatment. Minor/Significance Unknown.

Lomitapide dose should not exceed 30 mg/day. Musculoskeletal and connective tissue disorders: Muscle spasms, Respiratory, thoracic and mediastinal disorders: Pulmonary embolism (in some cases fatal), Hematologic disorders: Secondary acute myelogenous leukemia, Skin and subcutaneous tissue disorders: Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, lichenoid keratosis, History of severe hypersensitivity to doxorubicin, including anaphylaxis, Serious and sometimes life-threatening infusion-related reactions reported; ensure that medications to treat infusion-related reactions and cardiopulmonary resuscitative equipment are available for immediate use prior to initiation (see Black Box Warnings), Incidence of hand-foot syndrome in 1 trial was 51%, including 24% grade 3 or 4 toxicity (see Dosage Modifications), Secondary oral cancers, primarily squamous cell carcinoma, have been reported, Based on animal data, can cause fetal harm when administered to pregnant women, Based on findings in animals and its mechanism of action, therapy can cause fetal harm when administered to a pregnant woman; avoid use during the 1st trimester, Verify the pregnancy status of females of reproductive potential prior to initiating therapy, Not known whether drug is present in human milk; because many drugs, including anthracyclines, are excreted in human milk and because of the potential for serious adverse reactions in breastfed infants from therapy, discontinue breastfeeding during treatment. etravirine will decrease the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor for doxorubicin-induced cardiovascular toxicity. endobj fosamprenavir will increase the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Monitor Closely (1)duvelisib will increase the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)doxorubicin liposomal will increase the level or effect of lemborexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. doxorubicin liposomal decreases levels of digoxin by inhibition of GI absorption. Minor (1)armodafinil will decrease the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. endobj sorafenib, doxorubicin liposomal. doxorubicin liposomal, tofacitinib. trastuzumab, doxorubicin liposomal. Adjust dose of drugs that are CYP3A4 substrates as necessary. informational and educational purposes only. Normal hair growth should return several months after treatment has ended.Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Use Caution/Monitor. endstream Serious - Use Alternative (1)doxorubicin liposomal will decrease the level or effect of edoxaban by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown. doxorubicin liposomal increases toxicity of mercaptopurine by pharmacodynamic synergism. Use Caution/Monitor.Serious - Use Alternative (1)nefazodone will increase the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. endobj Minor/Significance Unknown. Use Caution/Monitor. Use Caution/Monitor.nilotinib will increase the level or effect of doxorubicin liposomal by P-glycoprotein (MDR1) efflux transporter. It may decrease this medication's effects. Concomitant therapy is expected to increase the risk of immunosuppression. Liposomal doxorubicin may harm an unborn baby. doxorubicin, pegylated liposomal intravenous. Use Caution/Monitor. Use Caution/Monitor. commonly, these are "non-preferred" brand drugs. Modify Therapy/Monitor Closely. streptozocin increases levels of doxorubicin liposomal by decreasing metabolism.

rifampin will decrease the level or effect of doxorubicin liposomal by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. fedratinib will increase the level or effect of doxorubicin liposomal by affecting hepatic enzyme CYP2D6 metabolism. This information is not individual medical advice and does not substitute for the advice of your health care professional. Minor/Significance Unknown. Use Caution/Monitor. Consider dose reduction of sensitive P-gp substrates. If not feasible, avoid use of abametapir. Minor/Significance Unknown. endobj Monitor Closely (1)nelfinavir will increase the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor (1)doxorubicin liposomal will increase the level or effect of ruxolitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. For information about enrolling in MedicAlert, call 1-888-633-4298 (US) or 1-800-668-1507 (Canada). Monitor Closely (1)doxorubicin liposomal increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Use Caution/Monitor.rifampin will decrease the level or effect of doxorubicin liposomal by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. 173 0 obj Lipo-Dox is contraindicated in patients who have a history hypersensitivity to doxorubicin HCl or the excipient of Lipo-Dox. dabrafenib will decrease the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Incidence and severity was highest when used with anthracycline-containing chemotherapy regimens. doxorubicin liposomal will increase the level or effect of isavuconazonium sulfate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. MISSED DOSE: It is important to get each dose of this medication as scheduled. Increased risk of hepatotoxicity. Nausea and vomiting can be severe. nefazodone will increase the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor Closely (2)eliglustat increases levels of doxorubicin liposomal by P-glycoprotein (MDR1) efflux transporter. abametapir will increase the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. immunosuppressive effects; risk of infection. Monitor sensitive CYP3A4 substrates for effectiveness if coadministered. Monitor for doxorubicin-induced cardiovascular toxicity. Monitor Closely (1)doxorubicin liposomal increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)terbinafine will increase the level or effect of doxorubicin liposomal by affecting hepatic enzyme CYP2D6 metabolism. efavirenz will decrease the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)doxorubicin liposomal will increase the level or effect of atogepant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)ivosidenib will decrease the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rifabutin will decrease the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Use Caution/Monitor. 174 0 obj Modify Therapy/Monitor Closely. Monitor Closely (1)doxorubicin liposomal will increase the level or effect of tinidazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature. Assess need to reduce dose of CYP2D6-metabolized drug. Use Caution/Monitor. belzutifan will decrease the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. 0000048653 00000 n Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations.

• Taiwan To Vancouver Flight Time
• How Many Chipmunks Are There In The World
• Sonoma County Library Card
• Quantum Synonym And Antonym
• Multimeter Calibration Certificate Pdf
• Car Insurance Discounts For Healthcare Workers
• Glow In The Dark Shirts Walmart
• Lowest Paid Mlb Player 2022